We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-9.62%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$327M
AUM Growth
-$243M
Cap. Flow
-$162M
Cap. Flow %
-49.62%
Top 10 Hldgs %
69.58%
Holding
50
New
3
Increased
3
Reduced
–
Closed
9

Top Buys

Rank Stock Value
1
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$38.8M
2
INZY
Inozyme Pharma
INZY
+$7.95M
3
GOSS icon
Gossamer Bio
GOSS
+$7.06M
4
IOBT
IO Biotech
IOBT
+$4.63M
5
HLVX
HilleVax
HLVX
+$2.81M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$198M
2
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$12.1M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$9.42M
4
DBTX
Decibel Therapeutics, Inc. Common Stock
DBTX
+$3.09M
5
ELEV
Elevation Oncology
ELEV
+$1.26M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Financials 0.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MLYS icon
1
Mineralys Therapeutics
MLYS
$2.35B
$43M 13.16%
4,519,361
– –
RYZB
2
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$41M 12.54%
+1,845,948
New +$38.8M
SRRK icon
3
Scholar Rock
SRRK
$5.71B
$32.7M 9.99%
4,598,828
– –
SLRN
4
DELISTED
ACELYRIN
SLRN
$24.2M 7.41%
2,381,579
+125,557
+6% +$2.67M
ACLX
5
DELISTED
Arcellx
ACLX
$22M 6.74%
613,921
– –
LENZ
6
LENZ Therapeutics
LENZ
$172M
$21M 6.42%
1,208,473
– –
ICPT
7
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$11.9M 3.64%
640,688
– –
LYRA
8
DELISTED
LYRA THERAPEUTICS INC
LYRA
$10.9M 3.33%
55,605
– –
HLVX
9
DELISTED
HilleVax
HLVX
$10.8M 3.29%
799,274
+200,000
+33% +$2.81M
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$9.97M 3.05%
967,527
– –
ZYME icon
11
Zymeworks
ZYME
$1.68B
$9.25M 2.83%
1,458,875
– –
RYTM icon
12
Rhythm Pharmaceuticals
RYTM
$7B
$7.92M 2.42%
345,293
– –
TNGX icon
13
Tango Therapeutics
TNGX
$4.34B
$7.09M 2.17%
630,000
– –
INZY
14
DELISTED
Inozyme Pharma
INZY
$6.56M 2.01%
+1,562,500
New +$7.95M
STRO icon
15
Sutro Biopharma
STRO
$379M
$5.81M 1.78%
167,558
– –
VRNA
16
DELISTED
Verona Pharma
VRNA
$5.66M 1.73%
347,500
– –
IOBT
17
DELISTED
IO Biotech
IOBT
$5.13M 1.57%
3,640,015
+2,631,578
+261% +$4.63M
GOSS icon
18
Gossamer Bio
GOSS
$66.5M
$5.11M 1.56%
+6,130,268
New +$7.06M
ACRS icon
19
Aclaris Therapeutics
ACRS
$730M
$4.77M 1.46%
696,171
– –
IMTX icon
20
Immatics
IMTX
$1.24B
$4.59M 1.4%
396,000
– –
PRME icon
21
Prime Medicine
PRME
$533M
$4.49M 1.37%
470,304
– –
IMCR icon
22
Immunocore
IMCR
$1.78B
$4.2M 1.29%
80,963
– –
NKTX icon
23
Nkarta
NKTX
$162M
$3.99M 1.22%
2,868,035
– –
JANX icon
24
Janux Therapeutics
JANX
$935M
$3.63M 1.11%
360,414
– –
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.48M 1.07%
881,450
– –
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
GSIS
Global Strategic Investment Solutions Scottsdale, Arizona $1.03B AUM 16.75% 1-Year Est. Return
RIM
RW Investment Management Eagle, Idaho $1.03B AUM
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return

Samsara BioCapital's Q3 2023 Portfolio in Review

As of Q3 2023, Samsara BioCapital held 50 positions worth $327M, down 43% from $570M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Samsara BioCapital withdrew a net $162M in Q3 2023, closing 9 positions. Its most notable exit was Chinook Therapeutics, Inc. Common Stock, an estimated $198M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

Against the trend, Samsara BioCapital opened a new position in RayzeBio, Inc. Common Stock worth $41M.

  • Samsara BioCapital's largest Q3 2023 buy was RayzeBio, Inc. Common Stock: 1,845,948 shares worth $41M.
  • Samsara BioCapital added most to IO Biotech in Q3 2023, an estimated $4.63M increase.
  • Samsara BioCapital fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $198M.
  • Samsara BioCapital's ten largest holdings make up 70% of its $327M portfolio in Q3 2023.
  • Samsara BioCapital opened 3 new positions and closed 9 in Q3 2023.
  • Samsara BioCapital's portfolio value fell 43% quarter-over-quarter to $327M.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.